跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,855 条关于
“M1/M4 muscarinic receptors”
全部
5,855
临床试验
3,613
药物
670
机构
7
资讯
1,565
去年
Cobenfy Shows Cognitive Benefits in Schizophrenia Patients with CANTAB Assessment
2年前
BMS Acquires Karuna Therapeutics for $14 Billion, Betting on Novel Schizophrenia Drug KarXT
24天前
FDA Clears IND for Neurocrine and Nxera's Oral M1 Agonist NBI-1117567 in Alzheimer's Cognition
去年
Xanomeline/Trospium Chloride (COBENFY™) Approved for Schizophrenia Treatment
去年
MapLight Therapeutics Initiates Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for Schizophrenia Treatment
8个月前
MapLight Therapeutics Receives FDA Fast Track Designation for Alzheimer's Disease Psychosis Treatment
去年
Bristol Myers Squibb Soars as AbbVie's Schizophrenia Drug Fails Trial
9个月前
China Approves COBENFY, First Novel Schizophrenia Therapy in Over 70 Years
去年
Bristol Myers Squibb Presents New COBENFY Data for Schizophrenia Treatment at Psych Congress
2年前
FDA Approves Cobenfy, a Novel Schizophrenia Treatment Targeting Cholinergic Receptors
第 1 页,共 157 页
上一页
下一页